We focus to look at key drivers of biotech stocks' price movement on 4 April 2025.

Renovaro Biosciences (NASDAQ:RENB) announced that Predictive Oncology (NASDAQ: POAI) terminated their merger agreement, which Renovaro claims is a breach of binding agreements. Renovaro is demanding compliance with the deal, including an exclusive license agreement, and may pursue legal action if unresolved by 10 April 2025. Renovario shares closed down 16% at US$0.39.

NeuroOne Medical (NASDAQ: NMTC) announced the pricing of an US$8 million underwritten registered public offering of 16m shares of its common stock for US$0.50 per share. Shares closed down 45% at US$0.48.

Sarepta Therapeutics (NASDAQ: SRPT) reported that an independent data monitoring committee reviewed safety data for ELEVIDYS after EU regulators flagged liver failure concerns. The committee upheld a favorable benefit-risk profile, allowing paused trials to continue. Sarepta and Roche will submit findings to regulators, with no expected impact on study timelines. Shares closed down 7% at US$54.43.

Sangamo Therapeutics (NASDAQ: SGMO) licensed its STAC-BBB AAV capsid to Eli Lilly for CNS disease treatments, securing an US$18 million upfront fee and potential milestone payments up to US$1.4 billion, plus tiered royalties on future sales. Shares closed up 6% at US$0.66.

Dynavax Technologies (NASDAQ: DVAX) filed preliminary proxy materials ahead of its 2025 annual meeting, highlighting ongoing strategy execution and nominating four independent directors (Brent MacGregor, Scott Myers, Lauren Silvernail, and Elaine Sun) for reelection. Shares closed down 2% at US$12.65.

Arvinas (NASDAQ: ARVN) reported first-in-human Phase 1 data for ARV-102, showing it was well tolerated and achieved robust, dose-dependent LRRK2 degradation in CSF and blood, supporting continued development in Parkinson’s and related neurodegenerative diseases. Shares closed down 5% at US$6.56.

OS Therapies (NASDAQ: OSTX) received a Buy rating and a US$19.00 price target from Lake Street. Shares closed down 9% at US$1.4.